about
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersCardiovascular safety of anti-diabetic drugsAnti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animalsHypoglycemic agents and potential anti-inflammatory activityCardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three StudiesIncretin physiology and pathophysiology from an Asian perspectiveNew insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-cateninIncretins and the intensivist: what are they and what does an intensivist need to know about them?Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsGlucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetesPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistanceInsulin Signaling and Heart Failure.A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.The identification of novel proteins that interact with the GLP-1 receptor and restrain its activityLinagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function.The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patientsImportance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.The potential role of incretin therapy in the hospital setting.Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort studyG protein-coupled receptors and the regulation of autophagy.Cardiovascular and hemodynamic effects of glucagon-like peptide-1.Benefits of healthy adipose tissue in the treatment of diabetes.The nonglycemic actions of dipeptidyl peptidase-4 inhibitorsPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemEffects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model.Cardiovascular effects of incretin therapy in diabetes care.GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.Emerging gliptins for type 2 diabetes.Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure.The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
P2860
Q26740443-87276849-1A0E-4FBB-96E3-7772AE70144AQ26741082-F4B5B54E-C55D-4CB4-A2C4-6704AC53A0A0Q26749176-52D07D99-09A6-496A-98C8-6F5BD512708AQ26750414-88ED8364-B6EF-4A94-A974-B807E7372A8AQ26752255-0FA8EF35-2BCF-4C21-A285-F0800494C85BQ26777177-21B829F2-07EB-4584-AFE1-BF7E40370598Q26784623-8CF36597-F43E-44AC-8212-2BEBFAA4BD8CQ26823824-4F5AC2ED-E423-4235-9E2B-7730F431B5C5Q26995464-7DC7E08D-1012-4356-974C-3369759968C1Q28077026-5F56190F-5B7D-4DE5-A886-38A35A41FDBBQ28081569-F5AADD6C-B30A-4ADB-8EFC-C493038364DFQ28546539-25AC76A2-354B-4A00-996B-B25D536374D6Q30249371-5BCC11F4-E426-4BDB-863D-EEE4827CA6F0Q30371576-6C37806B-0E7C-4FD4-B84F-DE29615E0B03Q30377910-AFBC10B5-7177-486D-8681-F7D1D476DAD7Q30437335-C04F58FF-8206-4AB0-A7DC-CDB882533D4DQ30597265-1D410755-D528-4A8D-9CCF-38FBF12BFE50Q33633076-DA67FFAD-A21C-4195-9028-25B0A70FAEC0Q33633664-24DB69AD-ED5B-4AB0-A7EB-825822AD0613Q33662677-1A27F043-9CFD-4680-AC2E-CA94FD7485BCQ33706621-8DAE07E2-8016-4DB8-9619-422487453073Q33789371-4F195731-8662-4957-8E51-71ABD6151EC9Q33792390-59C1185A-EFEF-439E-9AFE-AD9F35899D7EQ33833732-25CCE305-E75D-4490-89D2-BBEB2ECA5D69Q33847091-CB476127-BCD8-4B28-B044-472E46618B0EQ33993725-D1CDE0B1-AD0D-4AE1-B2E3-E8A21001B4E4Q34023537-7ACE7A2F-FC42-4CC9-B349-28436DF12E86Q34029715-D6249DB3-2359-4441-B9F8-D94928B8FAD3Q34062829-8905CE7D-9468-4DB6-804E-7D666EB0C89FQ34128774-8AA14714-38F3-4A87-A6AE-03583BD4D55DQ34171759-816BF8AC-E293-4B41-9ED4-ABF72ABBCDF4Q34336097-65D201FC-7176-4628-9234-DB06F55E6E15Q34347884-8D5B7AA3-8291-4C15-B408-89797688D170Q34396881-1398B752-A296-4938-82B4-F230E2F03506Q34503796-F77B151F-4859-4228-B4E6-B047C8A932FDQ34547492-75444C69-D676-4A6A-98B6-1B8F7CD063A0Q34559981-076B6703-58A4-46DC-97C5-9F4D091EED4FQ34603269-E54FCD82-DD9D-44E6-88CA-E76C0E6ED51FQ34640125-5886181D-0608-4AF8-97E3-7ECAA9027F56Q34658875-AA72F292-8D3C-4F9C-8A8D-F4F09D09740A
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cardiovascular biology of the incretin system.
@ast
Cardiovascular biology of the incretin system.
@en
type
label
Cardiovascular biology of the incretin system.
@ast
Cardiovascular biology of the incretin system.
@en
prefLabel
Cardiovascular biology of the incretin system.
@ast
Cardiovascular biology of the incretin system.
@en
P2860
P356
P1433
P1476
Cardiovascular biology of the incretin system.
@en
P2093
John R Ussher
P2860
P304
P356
10.1210/ER.2011-1052
P577
2012-02-08T00:00:00Z